Page 3 - Synlogic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Synlogic Inc. jolted Wall Street with news that the firm is scrapping for futility Synpheny-3, its pivotal study with labafenogene marselecobac (SYNB-1934) for phenylketonuria, and will evaluate strategic options. Shares of the Cambridge, Mass.-based firm (NASDAQ:SYBX) fell 48.7%, or $1.68, to end Feb. 9 at $1.77. Synlogic will cease operations and reduce its workforce by more than 90%, retaining only certain employees to help with the wind-down.

08.02.2024 - Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to perform assessment of strategic options ... Seite 1

Synlogic, Inc. (NASDAQ:SYBX – Get Free Report)’s share price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $3.23 and traded as low as $3.21. Synlogic shares last traded at $3.60, with a volume of 34,642 shares traded. Wall Street Analyst Weigh In Separately, Alliance […]

/PRNewswire/ -- The human microbiome therapeutics market is expected to grow by USD 732.95 million from 2022 to 2027. In addition, the momentum of the market...

Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age -…